Post-approval observational prospective study to evaluate the prevalence of the metabolic syndrome in prostate cancer patients both before and after a 12-monthtreatment with quarterly LHRH analogue formulations (ANAMET Study)

Study identification

• EU PAS number:
  EUPAS7866
• Study ID:
  38431
• Official title and acronym:
  Post-approval observational prospective study to evaluate the prevalence of the metabolic syndrome in prostate cancer patients both before and after a 12-monthtreatment with quarterly LHRH analogue formulations (ANAMET Study)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  This post-approval observational prospective study assesses the prevalence of metabolic syndrome in men with prostate cancer before and after 12 months of treatment with quarterly Luteinizing-hormone-releasing hormone (LHRH) analogues formulations.
• Study status:
  Finalised

Research institutions and networks

Institutions

Ipsen Pharma

Multiple centres: 42 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 22/10/2008

Actual: 22/10/2008

Study start date

Planned: 10/12/2008

Actual: 10/12/2008

Date of final study report

Planned: 12/11/2013

Actual: 12/11/2013

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Ipsen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable